Exicure Announces Presentation at Chardan’s 6th Annual Genetic Medicines Conference

Exicure, Inc. (NASDAQ: XCUR), an early-stage biotechnology company focused on the development of next generation nucleic acid therapies targeting RNA to address both genetic and non-genetic neurological disorders and hair loss disorders, today announced that CEO Matthias Schroff will provide a live presentation at the 2022 Chardan Genetic Medicines Conference, occurring October 3-4, 2022.

The presentation will be available for on-demand viewing using the virtual conference link beginning October 3, 2022 at 4:00 PM EST and will be archived for 120 days: https://wsw.com/webcast/chard14/xcur/1943406

Exicure will be taking 1x1 investor meetings with registered conference attendees.

About Exicure

Exicure, Inc. is an early-stage biotechnology company developing nucleic acid therapies targeting ribonucleic acid against validated targets to neurological disorders and hair loss. The team includes a diverse scientific group with expertise in nucleic acid chemistry, drug development and neuroscience. Headquartered in Chicago, Illinois, the Company conducts its discovery and development efforts in-house with a dedicated 30,000 square foot facility, including rapid and automated high throughput nucleic acid synthesis and screening. For further information, see www.exicuretx.com.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  218.71
-3.32 (-1.50%)
AAPL  260.17
-2.60 (-0.99%)
AMD  238.63
+0.60 (0.25%)
BAC  51.10
-0.42 (-0.81%)
GOOG  255.30
+3.96 (1.58%)
META  739.70
+6.43 (0.88%)
MSFT  523.41
+5.75 (1.11%)
NVDA  182.52
+1.36 (0.75%)
ORCL  275.01
-0.14 (-0.05%)
TSLA  440.76
-1.84 (-0.42%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.